Background: Rabacfosadine (RAB), a novel antineoplastic agent conditionally licensed for the treatment of lymphoma in dogs, is efficacious in both naïve and previously treated dogs. Its use in combination with L-asparaginase (L-ASP) has not been studied.
(DOX)-based chemotherapy protocols (ie, "CHOP-based" protocols including cyclophosphamide, DOX, vincristine, and prednisone) have been the staple of lymphoma treatment in dogs for over 20 years. 1 These protocols are highly effective in inducing remission for most dogs; however, more than 95% of dogs relapse with CHOP-refractory disease. Chemotherapy-refractory disease presents the greatest challenge for clinicians treating lymphoma, and there thus remains a need for novel antineoplastic agents and protocols for the treatment of lymphoma in dogs.
Rabacfosadine (RAB, Tanovea-CA1; VetDC, Fort Collins, CO), previously known as VDC-1101 or GS-9219, is a novel nucleotide analog antineoplastic prodrug. The mechanism of action has been previously reported in depth. 2, 3 Briefly, RAB is preferentially taken up by lymphoid cells and metabolized to 9-(2-phosphonylmethoxyethyl guanine), which then inhibits DNA synthesis/repair after being doubly phosphorylated.
Rabacfosadine has efficacy for treatment of lymphoma in dogs in both naïve and relapsed cases. [2] [3] [4] Rabacfosadine administration has an objective response rate of 74% when used as a single agent for dogs with relapsed multicentric B-cell lymphoma. 4 Similar to most other cytotoxic agents, RAB seems to be more effective in treating multicentric B-cell lymphomas in comparison to T-cell lymphomas. 2 Rabacfosadine has conditional approval from the US Food and Drug Administration for the treatment of lymphoma in dogs. The rec- L-asparaginase (L-ASP) is an enzyme commonly used in the treatment of lymphoma in dogs. It acts by depleting systemic asparagine/glutamine which leads to decreased capacity for protein synthesis and apoptosis of cells lacking asparagine synthetase, such as lymphocytes. 5, 6 Adverse events reported in dogs include hypersensitivity reactions, abnormal liver function tests, altered coagulation measurements, and pancreatitis. 7 In humans, it is predominantly used in the treatment of acute lymphoblastic leukemia (ALL). The addition of L-ASP to ALL protocols has significantly increased long-term survival for children with ALL. 8, 9 In dogs, it is used in both naïve and rescue lymphoma settings. 7,10-13 However, despite its common use for lymphoma in dogs, no prospective studies have been conducted demonstrating a clinical benefit when adding L-ASP to combination chemotherapy protocols. 12, 14 The objective of this study was to evaluate the safety and efficacy of RAB in combination with L-ASP for the treatment of relapsed multicentric lymphoma in dogs. This was accomplished through the conduct of an open-label, prospective, single-arm clinical trial. 15 Dogs were excluded from the study if they had received chemotherapy within 1 week of enrollment, had received RAB before enrollment, had received radiation therapy within 6 weeks of enrollment, had pulmonary fibrosis or a history of chronic pulmonary disease that could predispose to fibrosis, had concurrent malignancy or significant comorbidities, had previously been treated with bleomycin, or were receiving alternative therapies within a day of enrollment (permitted supplements included chondroitin sulfate, vitamins, essential fatty acids, glucosamine). Dogs having received L-ASP previously were permitted so long as they had not received a dose within 1 week of enrollment. West Highland White Terriers were excluded because of a genetic predisposition for idiopathic pulmonary fibrosis. Staging tests such as abdominal ultrasound and bone marrow aspiration cytology were recorded if performed previously but were not required for enrollment in the study. Thoracic radiographs were highly recommended before enrollment, but not required. Recorded variables included signalment (eg, age, sex, neuter status, breed, body weight), immunophenotype, and previous treatment (corticosteroids, previous chemotherapy protocols, etc.).
| MATERIALS AND METHODS
Rabacfosadine was provided by VetDC, Inc. Signed informed consent was obtained from all owners before study entry. All dogs received RAB at a dose of 1.0 mg/kg. Rabacfosadine was reconstituted and diluted with sodium chloride for injection, USP to achieve a total infusion volume of 2 mL/kg, and was administered IV as a 30-minute infusion. Rabacfosadine was administered every 3 weeks up to a total of 5 doses per the label instructions. L-asparaginase was administered SC at a dose of 400 IU/kg, concurrent with the first 2 treatments of RAB. In dogs whose calculated L-ASP dose was between 10 000 and 15 000 IU, the dose was rounded down to 10 000. Dogs whose calculated dose was <10 000 IU or >15 000 IU received exactly 400 IU/kg. Concurrent use of steroid treatment was allowed in this study and no standard dose or dosing scheme was dictated by the trial design. Prophylactic anti-nausea and anti-diarrheal medications were permitted and prescribed based on individual clinician discretion. Antihistamines were also permitted as pretreatment for L-ASP.
Response to treatment was determined by using the Veterinary Cooperative Oncology Group (VCOG) response evaluation criteria for lymphoma. 16 A complete response (CR) was defined as disappearance of all evidence of disease. A partial response (PR) was defined as 
| RESULTS

| Dog population
Fifty-two dogs in total were prospectively enrolled in the study. 
Monthly rechecks X Recommended every other month previous treatment before RAB/L-ASP is given in Table 2 . A total of 9 of the 52 dogs (17%) did not receive concurrent steroid treatment.
Treatment was variable for all dogs receiving a concurrent steroid (prednisolone, prednisone, dexamethasone), including use of every other day dosing or a tapering course. Thirteen of the 52 dogs (25%)
received an antihistamine before treatment for at least 1 of the L-ASP treatments.
| Adverse events
Fifty-two dogs were evaluable for assessment of AEs. Forty-three dogs (81%) had at least 1 AE reported during their treatment protocol.
Frequency of the most commonly reported AEs are summarized in Table 3 . The most common AEs were GI in origin, with grade 1 GI AEs being more common than grade 2 or 3 GI AEs. Two dogs experienced Degree of pretreatment and before L-ASP treatment was found to significantly affect PFS (Figures 1 and 2) . Dogs that only had 1 line of previous treatment had an MPFS of 86 days, dogs with 2 lines of treatment had an MPFS of 42 days, and dogs with ≥3 lines of treatment had an MPFS of 31.5 days (logrank test for trend P = .0004).
| Dog outcomes
Dogs having been treated with only 1 previous therapeutic protocol were significantly more likely to achieve a CR (61%, ORR = 74%). For dogs treated with 2 previous protocols the ORR was 73%, with only 27% achieving a CR (Figure 3 ). No dogs having been treated with 3 or more previous protocols achieved a CR, and only 50% of these dogs had a response to treatment. Previous treatment with L-ASP significantly impacted CR rates, with dogs not having previously been treated with L-ASP significantly more likely to achieve a CR (Figure 4 ; P = .001). Dogs not previously treated with L-ASP had an MPFS of 86 days compared to 38 days for those previously treated with L-ASP before enrollment ( Figure 2 ; logrank P = .0007).
The MPFS was 63 days (range 14-428 days) for B-cell lymphoma and 43 days (5-86 days) for dogs with T-cell lymphoma (Figure 4 ). The ORR for dogs with B-cell lymphoma was 73.3% with 50% achieving a CR ( Figure 5 ). Dogs with T-cell lymphoma had an ORR of 62.5% with 12.5% achieving a CR (P > .05). 
| DISCUSSION
The results of this study suggest that the combination of RAB and L-ASP is both safe and efficacious for dogs with relapsed multicentric lymphoma. The ORR for all dogs treated in this study was 70%, with 41% experiencing a CR. The MPFS for all dogs was 63 days, and 144 days for dogs achieving a CR. The majority of AEs seen in this study population were self-limiting, and similar in frequency/severity to previously reported studies evaluating RAB. 4, 17 Five dogs were withdrawn from the study because of AEs, and the majority of these were caused by grade 3 hyporexia/weight loss. Of these 5 dogs, 2 of them had a 20% dose reduction of RAB but were later withdrawn because of continued AEs. The other 8 dogs who had RAB dose reduced were able to continue receiving RAB at a reduced dose or were withdrawn shortly after because of PD. One dog developed radiographic signs suspicious for pulmonary fibrosis 167 days after treatment initiation but had no clinical signs. A total of 15 dogs developed a dermatologic AE, the majority of which were grade I/II and did not require dose alterations. No dogs experienced a grade 5 AE.
Dogs that were more heavily pretreated before initiating RAB/L-ASP had a significantly shorter MPFS (Figure 1 ). This could suggest that RAB shares resistance mechanisms to other agents used commonly in the treatment of multicentric lymphoma in dogs. Alternatively, previous che- which might activate pro-survival pathways. 19, 20 In this study, as is consistent with previous RAB studies, 17 The schedule for L-ASP administration in this current study was based on protocols combining L-ASP with CCNU. Two such protocols have been evaluated in the literature for relapsed lymphoma in dogs. 7, 13 The first study evaluated L-ASP concurrent with the first 2 treatments of CCNU and resulted in an ORR of 87%, with 52% achieving a CR. Median time to progression was 63 days. 7 The second study evaluated the continuous use of L-ASP with each treatment of CCNU and resulted in an ORR of 77%, with 65% of dogs achieving a CR. 13 Median time to progression for this study was 70 days. No obvious benefit is noted when comparing these studies, which led us to model our trial design after the first. This could be a limitation of our study as the clinical use of L-ASP has not been optimized for dogs with lymphoma. To this note, the efficacy of L-ASP is unquestioned for treating lymphoma in dogs; however, no prospective studies have been conducted with the goal of demonstrating an optimal dosing scheme for L-ASP as has been done for human leukemia. For this reason, it is unclear whether using infrequent L-ASP at the beginning of treatment, as was done in this study, is the best way to include L-ASP in a combination protocol. Further studies are required to evaluate the dosing schedule/intensity of L-ASP administration in dogs.
As stated previously, L-ASP is used most commonly in human medicine for the treatment of pediatric ALL, where it has been shown to improve 5-year survival when used as part of multi-agent F I G U R E 5 Response rates based on immunophenotype for dogs treated with RAB/L-ASP (n = 46) protocols. 8, 9 Furthermore, therapeutic drug monitoring via nadir serum asparaginase activity levels have been shown to improve outcomes. 8, 9, 21 Nadir serum asparaginase activity can be used to detect dogs who potentially have developed neutralizing antibodies, who then can be treated with Erwinia derived L-ASP or pegylated forms. 9, 22 Similarly, for people developing hypersensitivity reactions, other forms of L-ASP can be safely administered. The use of L-ASP in adult onset ALL is not as well understood because of increased risk of AEs, although this might be modified with appropriate therapeutic drug monitoring. 21, 23 The understanding of how L-ASP is used and monitored in people could be the basis of further studies which might lead to improved outcomes for lymphoma in dogs.
A major limitation of this study is the lack of a control arm.
Because of this study design, we cannot conclude on the superiority/ inferiority of this treatment protocol in comparison to single agent RAB for relapsed lymphoma in dogs. Furthermore, this study did not further the understanding of best treatment for relapsed lymphoma in dogs. Another limitation of this study is the variable steroid usage. Steroids are commonly used in lymphoma treatment protocols and could have masked poor responses and even AEs to RAB/L-ASP in certain dogs. Furthermore, dexamethasone and prednisone might have differing benefits in lymphoma and relapsed lymphoma, although the efficacy of one over the other is not well understood. Lastly, we cannot critically evaluate whether dogs have an increased risk of AEs when treated with RAB in combination with L-ASP versus RAB alone. However, only 10 dogs (19%) required a dose reduction in this current study. This is at least similar to a previous study where 34 dogs with relapsed B-cell lymphoma were treated with RAB at 1.0 mg/kg IV every 3 weeks, and 12 of these dogs (35%) were reported to have had a dose reduction. 4 In conclusion, RAB/L-ASP appears to be both safe and efficacious for dogs with relapsed multicentric lymphoma. Further studies are necessary to evaluate whether RAB/L-ASP offers any clinical benefit over RAB alone as a rescue protocol.
